Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

M. Di Bartolomeo; M. Niger; F. Morano; S. Corallo; M. Antista; S. Tamberi; S. Lonardi; S. Di Donato; R. Berardi; M. Scartozzi; G.G. Cardellino; F. Di Costanzo; L. Rimassa; A.G. Luporini; R. Longarini; A. Zaniboni; A. Bertolini; G. Tomasello; G. Pinotti; G. Scagliotti; G. Tortora; A. Bonetti; A. Spallanzani; G.L. Frassineti; D. Tassinari; F. Giuliani; S. Cinieri; E. Maiello; C. Verusio; S. Bracarda; V. Catalano; M. Basso; L. Ciuffreda; F. De Vita; H.S. Parra; L. Fornaro; M. Caporale; F. De Braud; F. Pietrantonio

doi:10.1186/s12885-019-5498-3

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

M. Di Bartolomeo, M. Niger, F. Morano, S. Corallo, M. Antista, S. Tamberi, S. Lonardi, S. Di Donato, R. Berardi, M. Scartozzi, G.G. Cardellino, F. Di Costanzo, L. Rimassa, A.G. Luporini, R. Longarini, A. Zaniboni, A. Bertolini, G. Tomasello, G. Pinotti, G. ScagliottiG. Tortora, A. Bonetti, A. Spallanzani, G.L. Frassineti, D. Tassinari, F. Giuliani, S. Cinieri, E. Maiello, C. Verusio, S. Bracarda, V. Catalano, M. Basso, L. Ciuffreda, F. De Vita, H.S. Parra, L. Fornaro, M. Caporale, F. De Braud, F. Pietrantonio

Research output: Contribution to journal › Article › peer-review

Original language	Italian
Journal	BMC Cancer
Volume	19
Issue number	1
DOIs	https://doi.org/10.1186/s12885-019-5498-3
Publication status	Published - 2019

Access to Document

10.1186/s12885-019-5498-3

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063752695&doi=10.1186%2fs12885-019-5498-3&partnerID=40&md5=32358601530afcae41583df05086246a

Cite this

Di Bartolomeo, M., Niger, M., Morano, F., Corallo, S., Antista, M., Tamberi, S., Lonardi, S., Di Donato, S., Berardi, R., Scartozzi, M., Cardellino, G. G., Di Costanzo, F., Rimassa, L., Luporini, A. G., Longarini, R., Zaniboni, A., Bertolini, A., Tomasello, G., Pinotti, G., ... Pietrantonio, F. (2019). Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial. BMC Cancer, 19(1). https://doi.org/10.1186/s12885-019-5498-3

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial. / Di Bartolomeo, M.; Niger, M.; Morano, F. et al.

In: BMC Cancer, Vol. 19, No. 1, 2019.

Research output: Contribution to journal › Article › peer-review

Di Bartolomeo, M, Niger, M, Morano, F, Corallo, S, Antista, M, Tamberi, S, Lonardi, S, Di Donato, S, Berardi, R, Scartozzi, M, Cardellino, GG, Di Costanzo, F, Rimassa, L, Luporini, AG, Longarini, R, Zaniboni, A, Bertolini, A, Tomasello, G, Pinotti, G, Scagliotti, G, Tortora, G, Bonetti, A, Spallanzani, A, Frassineti, GL, Tassinari, D, Giuliani, F, Cinieri, S, Maiello, E, Verusio, C, Bracarda, S, Catalano, V, Basso, M, Ciuffreda, L, De Vita, F, Parra, HS, Fornaro, L, Caporale, M, De Braud, F & Pietrantonio, F 2019, 'Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial', BMC Cancer, vol. 19, no. 1. https://doi.org/10.1186/s12885-019-5498-3

@article{20c880d3f31b456d8aba938131114089,

title = "Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial",

author = "{Di Bartolomeo}, M. and M. Niger and F. Morano and S. Corallo and M. Antista and S. Tamberi and S. Lonardi and {Di Donato}, S. and R. Berardi and M. Scartozzi and G.G. Cardellino and {Di Costanzo}, F. and L. Rimassa and A.G. Luporini and R. Longarini and A. Zaniboni and A. Bertolini and G. Tomasello and G. Pinotti and G. Scagliotti and G. Tortora and A. Bonetti and A. Spallanzani and G.L. Frassineti and D. Tassinari and F. Giuliani and S. Cinieri and E. Maiello and C. Verusio and S. Bracarda and V. Catalano and M. Basso and L. Ciuffreda and {De Vita}, F. and H.S. Parra and L. Fornaro and M. Caporale and {De Braud}, F. and F. Pietrantonio",

note = "Export Date: 25 February 2020",

year = "2019",

doi = "10.1186/s12885-019-5498-3",

language = "Italian",

volume = "19",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

AU - Di Bartolomeo, M.

AU - Niger, M.

AU - Morano, F.

AU - Corallo, S.

AU - Antista, M.

AU - Tamberi, S.

AU - Lonardi, S.

AU - Di Donato, S.

AU - Berardi, R.

AU - Scartozzi, M.

AU - Cardellino, G.G.

AU - Di Costanzo, F.

AU - Rimassa, L.

AU - Luporini, A.G.

AU - Longarini, R.

AU - Zaniboni, A.

AU - Bertolini, A.

AU - Tomasello, G.

AU - Pinotti, G.

AU - Scagliotti, G.

AU - Tortora, G.

AU - Bonetti, A.

AU - Spallanzani, A.

AU - Frassineti, G.L.

AU - Tassinari, D.

AU - Giuliani, F.

AU - Cinieri, S.

AU - Maiello, E.

AU - Verusio, C.

AU - Bracarda, S.

AU - Catalano, V.

AU - Basso, M.

AU - Ciuffreda, L.

AU - De Vita, F.

AU - Parra, H.S.

AU - Fornaro, L.

AU - Caporale, M.

AU - De Braud, F.

AU - Pietrantonio, F.

N1 - Export Date: 25 February 2020

PY - 2019

Y1 - 2019

U2 - 10.1186/s12885-019-5498-3

DO - 10.1186/s12885-019-5498-3

M3 - Articolo

VL - 19

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

ER -